ARK Diagnostics begins commercialization of anti-epileptic drug assays in Europe

Sunnyvale, California: ARK Diagnostics Inc. today announced the start of commercialization activities for CE-marked, new generation anti-convulsant drug assays in Europe. The monitoring of anti-epileptic drugs can provide clinicians valuable data for optimizing a patient’s medication regimen, especially in situations with complicating physiological or pharmacological factors.

ARK Diagnostics has developed proprietary homogeneous enzyme immunoassays for Lamotrigine, Levetiracetam, Zonisamide, Topiramate and Gabapentin. All are liquid-stable, ready-to-use reagents that can be adapted for use on a wide range of clinical chemistry systems. Today, these tests are typically performed on HPLC systems, however with the advent of the ARK products these tests can now join the routine laboratory repertoire thus enabling rapid result turnaround and improved patient monitoring.

ARK Diagnostics has partnered with KKPD, a Munich (Germany) based organization specialized in supporting companies to develop their European market position. The aim is to focus upon key laboratories across Europe and rapidly establish a customer base.

"We believe that ARK assays will be highly attractive to the laboratory. Our assays will allow laboratories to consolidate testing into their routine, and we are confident that our alliance with KKPD will allow us to target the right customers in Europe" said Johnny Valdez, President ARK Diagnostics.

ARK Diagnostics, Inc. makes homogeneous enzyme immunoassays for therapeutic drug management (TDM). Founded in 2003, ARK Diagnostics is a privately held company in Sunnyvale, CA and is certified to ISO 13485:2003 CMDCAS. ARK is dedicated to the design, development, and manufacture of TDM assays for personalizing therapy and improving the quality of patient health. For more information, visit www.ark-tdm.com

KKPD GbR is a Munich, Germany based organization specializing in working with IVD companies that manufacture novel or innovative products. KKPD works with these companies to define and develop their European market. For more information, visit www.kkpd.net.

For further information
USA: Don Ross, VP Marketing & Business Development, 650.465.3173, don@ark-tdm.com
EU: Paul Kenny, paul@ark-tdm.com or info@kkpd.net